meta
|
evidence
oncology
Living systematic review and meta-analysis
multiple myeloma - 1st line (L1)
1
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab plus lenalidomide and dexamethasone
versus all
vs Immunosuppressant
vs lenalidomide based treatment
vs lenalidomide and dexamethasone
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
Statistically conclusive or suggested result
Inconclusive results
Uncertain results
Safety results
multiple myeloma - 1st line (L1)
multiple myeloma - 1st line (L1)
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open